|
Dirk Thye is the Vice President of Clinical Development at Cerexa. Dr. Thye has extensive experience in anti infective research and clinical development in both domestic and international markets. Prior to joining Cerexa Dr. Thye was a founder and Sr. Vice President of Clinical Development at Peninsula Pharmaceuticals where he was responsible for the clinical development of Peninsula’s anti infective portfolio. Prior to founding Peninsula Dr. Thye led the clinical development program at Vicuron Pharmaceuticals for anidulafungin a systemic antifungal compound which has been approved for commercial use and was subsequently acquired by Pfizer in 2005. Dr. Thye is board certified in Internal Medicine and graduated with honors from UCLA School of Medicine. He completed his post graduate training in Internal Medicine at the Stanford University Medical Center. Dr. Thye also holds a Bachelor of Arts degree in Molecular Biology from the University of California at Berkeley. | 